title: Concomitant use of antipsychotics and drugs that may prolong the QT interval.
abstract: Concomitant use of drugs that prolong the QT interval is a risk factor for torsades de pointes, a ventricular arrhythmia associated with sudden death. This study compared the concomitant use of drugs that may prolong the QT interval ("other QT drugs") among two groups of patients: one that took antipsychotics that may prolong the QT interval (the QT antipsychotic group, n = 1,750) and one that used antipsychotics that do not result in QT prolongation (the non-QT antipsychotic group, n = 1,139). Data were pharmacy claim and eligibility information from January 1, 2000, through December 31, 2000, from a research database of a large pharmacy benefit manager. Concomitant use of antipsychotics and other QT drugs was examined for each participant over a 3- to 12-month follow-up period. Results showed that 51% of QT antipsychotic group members used other QT drugs concomitantly for at least 1 day in the follow-up period. Logistic regression indicated that there was no significant difference between the QT antipsychotic and non-QT antipsychotic groups with concomitant use of other QT drugs when potential confounders were controlled ( p = 0.6013). Although female sex is a risk factor for drug-induced torsades de pointes, women were more likely to concomitantly use other QT drugs than men in both the QT (56.2% vs. 43.2%; p < 0.001) and non-QT (53.1% vs. 43.0%;p < 0.001) antipsychotic groups. Findings suggest that the use of other QT drugs is not being minimized among patients taking QT antipsychotics.
authors.affiliation: Division of Biostatistics and Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA. cathyr@wubios.wustl.edu
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Roe
authors.forename: Kevin W
authors.initials: KW
authors.lastname: Odell
authors.forename: Rochelle R
authors.initials: RR
authors.lastname: Henderson
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D003625:Data Collection; D016208:Databases, Factual; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D012737:Sex Factors; D016171:Torsades de Pointes / Q000139:chemically induced* / Q000517:prevention & control
chemical_list: D014150:Antipsychotic Agents